Page last updated: 2024-10-23

buflomedil and Disease Exacerbation

buflomedil has been researched along with Disease Exacerbation in 3 studies

buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure

Research Excerpts

ExcerptRelevanceReference
" We performed an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate whether long-term administration of oral buflomedil could reduce the rate of cardiovascular events in patients with intermittent claudication."5.13Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. ( Becker, F; Leizorovicz, A, 2008)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
De Backer, TL1
Vander Stichele, RH1
Van Bortel, LM1
Leizorovicz, A1
Becker, F1
Conte, MS1

Trials

2 trials available for buflomedil and Disease Exacerbation

ArticleYear
Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".
    Circulation, 2008, Sep-02, Volume: 118, Issue:10

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Disease Progr

2008
Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    Circulation, 2008, Feb-12, Volume: 117, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Disease Progr

2008

Other Studies

1 other study available for buflomedil and Disease Exacerbation

ArticleYear
Buflomedil in peripheral arterial disease: trials and tribulations.
    Circulation, 2008, Feb-12, Volume: 117, Issue:6

    Topics: Adrenergic alpha-Antagonists; Cardiovascular Diseases; Disease Progression; Humans; Intermittent Cla

2008